Conduction System Stimulation to Avoid Left Ventricle Dysfunction

Circ Arrhythm Electrophysiol. 2024 Feb;17(2):e012473. doi: 10.1161/CIRCEP.123.012473. Epub 2024 Jan 29.

Abstract

Background: Right ventricular apical pacing (RVAP) can produce left ventricle dysfunction. Conduction system pacing (CSP) has been used successfully to reverse left ventricle dysfunction in patients with left bundle branch block. To date, data about CSP prevention of left ventricle dysfunction in patients with preserved left ventricular ejection fraction (LVEF) are scarce and limited mostly to nonrandomized studies. Our aim is to demonstrate that CSP can preserve normal ventricular function compared with RVAP in the setting of a high burden of ventricular pacing.

Methods: Consecutive patients with a high-degree atrioventricular block and preserved or mildly deteriorated LVEF (>40%) were included in this prospective, randomized, parallel, controlled study, comparing conventional RVAP versus CSP.

Results: Seventy-five patients were randomized, with no differences between basal characteristics in both groups. The stimulated QRS duration was significantly longer in the RVAP group compared with the CSP group (160.4±18.1 versus 124.2±20.2 ms; p<0.01). Seventy patients were included in the intention-to-treat analyses. LVEF showed a significant decrease in the RVAP group at 6 months compared with the CSP group (mean difference, -5.8% [95% CI, -9.6% to -2%]; P<0.01). Left ventricular end-diastolic diameter showed an increase in the RVAP group compared with the CSP group (mean difference, 3.2 [95% CI, 0.1-6.2] mm; P=0.04). Heart failure-related admissions were higher in the RVAP group (22.6% versus 5.1%; P=0.03).

Conclusions: Conduction system stimulation prevents LVEF deterioration and heart failure-related admissions in patients with normal or mildly deteriorated LVEF requiring a high burden of ventricular pacing. These results are only short term and need to be confirmed by further larger studies.

Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT06026683.

Keywords: atrial fibrillation; atrioventricular block; cardiac resynchronization therapy; humans; ventricular function, left.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Cardiac Conduction System Disease
  • Cardiac Pacing, Artificial / adverse effects
  • Cardiac Pacing, Artificial / methods
  • Cardiac Resynchronization Therapy*
  • Cardiomyopathies*
  • Heart Failure*
  • Heart Ventricles
  • Humans
  • Prospective Studies
  • Stroke Volume
  • Treatment Outcome
  • Ventricular Function, Left / physiology

Associated data

  • ClinicalTrials.gov/NCT06026683